For example, Ha et al. previously showed that only 1 in 3 patients with inflammatory bowel disease (IBD) in routine clinical practice would have qualified for the pivotal trials evaluating the efficacy and safety of TNF antagonists,9 and similar findings have been shown in RCTs of other chronic inflammatory diseases.10,11. Here, TNF is linked to irritable bowel syndrome.